Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
191.4 BRL | +11.35% |
|
+0.55% | -0.57% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- With an expected P/E ratio at 200.68 and 13.27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.76 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.57% | 8.55TCr | - | ||
+55.32% | 82TCr | C+ | ||
+44.05% | 64TCr | B | ||
-6.75% | 35TCr | C+ | ||
+13.56% | 31TCr | B- | ||
+10.68% | 30TCr | C+ | ||
+16.57% | 24TCr | B+ | ||
+13.31% | 22TCr | B- | ||
+8.48% | 17TCr | C+ | ||
-2.81% | 16TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GILD Stock
- GILD34 Stock
- Ratings Gilead Sciences, Inc.